Sanofi partners with Novavax on COVID-19 vaccine
Ticker: SNYNF · Form: 6-K · Filed: May 28, 2024 · CIK: 1121404
| Field | Detail |
|---|---|
| Company | Sanofi (SNYNF) |
| Form Type | 6-K |
| Filed Date | May 28, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: partnership, vaccine, licensing-agreement
Related Tickers: NVAX
TL;DR
Sanofi inks Novavax deal for COVID vaccine co-commercialization & combo shot development.
AI Summary
On May 10, 2024, Sanofi announced a co-exclusive licensing agreement with Novavax to co-commercialize Novavax's COVID-19 vaccine and develop a novel flu-COVID combination vaccine. This collaboration aims to leverage Sanofi's global reach and Novavax's vaccine technology.
Why It Matters
This partnership could expand Sanofi's vaccine portfolio and potentially offer new combination vaccines, impacting public health preparedness and the vaccine market.
Risk Assessment
Risk Level: low — The filing is a routine report of press releases and does not contain significant new financial or operational information that would inherently increase risk.
Key Players & Entities
- Sanofi (company) — Registrant and partner
- Novavax (company) — Partner
- May 10, 2024 (date) — Date of press release
FAQ
What is the nature of the agreement between Sanofi and Novavax?
Sanofi and Novavax announced a co-exclusive licensing agreement to co-commercialize Novavax's COVID-19 vaccine and develop a novel flu-COVID combination vaccine.
What is the date of the press release announcing this agreement?
The press release was dated May 10, 2024.
What are the key components of the Sanofi-Novavax collaboration?
The collaboration involves co-commercializing Novavax's existing COVID-19 vaccine and jointly developing a new vaccine that combines protection against both influenza and COVID-19.
What form is this SEC filing?
This is a Form 6-K report of Foreign Private Issuer.
What is Sanofi's primary business sector?
Sanofi's Standard Industrial Classification is Pharmaceutical Preparations [2834].
Filing Stats: 285 words · 1 min read · ~1 pages · Grade level 11.5 · Accepted 2024-05-28 12:04:28
Filing Documents
- d839421d6k.htm (6-K) — 11KB
- d839421dex991.htm (EX-99.1) — 22KB
- d839421dex992.htm (EX-99.2) — 21KB
- d839421dex993.htm (EX-99.3) — 39KB
- d839421dex994.htm (EX-99.4) — 18KB
- d839421dex995.htm (EX-99.5) — 26KB
- g839421g0527225640753.jpg (GRAPHIC) — 3KB
- g839421g06x08.gif (GRAPHIC) — 1KB
- 0001193125-24-147826.txt ( ) — 143KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: May 28, 2024 SANOFI By /s/ Alexandra Roger Name: Alexandra Roger Title: Head of Legal Corporate & Finance 3